Sodium hyaluronate eye drops and preparation method thereof
By controlling the pH value and adding specific ingredients, the preparation process of sodium hyaluronic acid eye drops is simplified, and the problems of long dissolution time, poor stability and high risk of bacterial infection are solved, and the stability and antibacterial effect of the product are improved. .
Patent Information
- Application Number
- CN202411030077.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-15
AI Technical Summary
During the preparation process, existing sodium hyaluronate eye drops have problems such as long dissolution time, complex production process, poor product stability and high risk of bacterial infection. Especially when used for a long time, antibacterial agents may reduce the activity of corneal conjunctival cells and cause inflammation.
By controlling the pH value in the range of 6.0-7.0 when preparing sodium hyaluronic acid eye drops, specific ingredients such as benzalkonium chloride, sodium chloride, potassium chloride, ε-aminocaproic acid and sodium edeate hydrate are added by controlling the pH value in the range of 6.0-7.0. , and heat and stir in a water bath at 40℃-60℃ to simplify the process flow, improve product stability and reduce bacterial infection risk.
It has achieved the shortening of the dissolution time of sodium hyaluronate, simplified production process, improved product stability, reduced the chance of bacterial infection, and maintained efficient antibacterial ability, which is suitable for long-term use.
Smart Images

Figure BDA0004969691070000051 
Figure BDA0004969691070000071 
Figure BDA0004969691070000072
Abstract
Description
Technical Field
[0001] The invention relates to the field of liquid preparations, in particular to sodium hyaluronate eye drops and a preparation method thereof. Background Art
[0002] Dry eye syndrome is a general term for a variety of diseases caused by abnormal tear quality or dynamics due to any reason, which leads to decreased tear film stability, accompanied by eye discomfort and / or ocular surface tissue lesions. It is also called keratoconjunctivitis sicca. Clinical manifestations include dry eyes, fatigue, itchy eyes, foreign body sensation, burning sensation, sticky secretions, fear of wind, fear of light, and sensitivity to external stimuli. The common product for treating dry eye syndrome is sodium hyaluronate eye drops.
[0003] Sodium hyaluronate, also known as sodium hyaluronate (HA-Na), is an acidic mucopolysaccharide macromolecule obtained by the extraction method of cockscomb or microbial fermentation. It is a biomacromolecule with high viscoelasticity and excellent biocompatibility. It can significantly prolong the tear film breakup time and has a good protective effect on the cornea and conjunctiva. Sodium hyaluronate is a white fibrous or powdery solid at room temperature. It has strong hygroscopicity, is soluble in water, and is insoluble in organic solvents. It can be used as an auxiliary drug for ophthalmic surgery and an auxiliary treatment for deformed knee arthritis and periarthritis of the shoulder. It also has important physiological functions in tissue generation, wound healing, tumor invasion and regulation of cell function. Sodium hyaluronate is mainly used as a raw material for medical sodium hyaluronate gel for ophthalmic surgery and sodium hyaluronate injection for orthopedics.
[0004] Since sodium hyaluronate is a large molecular mucopolysaccharide, its molecular weight is reduced under the influence of some physical and chemical factors, and it is not suitable for long-term storage at room temperature. At the same time, it is also conducive to bacterial growth. Therefore, there is a risk of bacterial contamination during the preparation of eye drops.
[0005] To solve this problem, antibacterial agents can be added to sodium hyaluronate eye drops, such as the multi-dose sodium hyaluronate eye drops developed by Japan Santen Pharmaceutical Co., Ltd., which contains 0.1% HA-Na5mL of antibacterial agents; single-dose packaging can also be used, such as Japan Santen Pharmaceutical Co., Ltd.'s preservative-free 0.1% and 0.3% HA-Na0.4ml; or special sterile devices can be used, such as URSA PHARM Arzneimittel GmbH's Sea Dew Sodium Hyaluronate Eye Drops 0.1% HA-Na10ml.
[0006] However, sodium hyaluronate eye drops containing commonly used antibacterial agents are not suitable for long-term use, because long-term use of antibacterial agents can reduce the survival activity of corneal and conjunctival epithelial cells, cause corneal and conjunctival damage, and induce inflammation, and are not suitable for sensitive people; the production cost of sodium hyaluronate eye drops without antibacterial agents in single-dose packaging or sterile devices will undoubtedly increase significantly. Therefore, there is an urgent need for a preparation process that simplifies the process, increases product stability, and reduces the risk of contamination during the preparation process of sodium hyaluronate eye drops. Summary of the invention
[0007] The purpose of the present invention is to provide a sodium hyaluronate eye drop and a preparation method thereof, so as to save the sodium hyaluronate dissolution time and the total time for producing the sodium hyaluronate eye drop, simplify the production process, improve the product stability and reduce the probability of bacterial contamination.
[0008] To achieve the above-mentioned purpose of the invention, the technical solution of the present invention is as follows:
[0009] According to a first aspect of the present invention, a sodium hyaluronate eye drop is provided, wherein the pH value of the sodium hyaluronate eye drop is 6.0-7.0; each 100 mL of the sodium hyaluronate eye drop comprises the following ingredients: 250-350 mg of sodium hyaluronate, 2.6-3.4 mg of benzalkonium chloride, 650-750 mg of sodium chloride, 100-200 mg of potassium chloride, 100-300 mg of ε-aminocaproic acid and 50-200 mg of sodium edetate hydrate.
[0010] In one aspect of the present invention, the pH value of the sodium hyaluronate eye drops is 6.4-6.8; preferably, the pH value of the sodium hyaluronate eye drops is 6.4-6.6.
[0011] In one aspect of the present invention, the sodium hyaluronate eye drops contain the following ingredients per 100 mL: 275-325 mg sodium hyaluronate, 2.8-3.2 mg benzalkonium chloride, 680-720 mg sodium chloride, 125-175 mg potassium chloride, 175-225 mg ε-aminocaproic acid and 75-125 mg sodium edetate hydrate.
[0012] In one aspect of the present invention, the edetate sodium hydrate is edetate disodium.
[0013] According to a first aspect of the present invention, a method for preparing sodium hyaluronate eye drops is provided, the method comprising the following steps:
[0014] Step 1: Place 80 mL of water in a container, heat it in a water bath at 40° C.-60° C., and sequentially add sodium chloride, potassium chloride, ε-aminocaproic acid, sodium edetate hydrate and benzalkonium chloride; adjust the pH value to 6.0-7.0; and obtain the solution of step 1;
[0015] Step 2: adding sodium hyaluronate to the solution prepared in step 1, stirring at the same water bath temperature as step 1 until it is completely dissolved, to obtain the solution prepared in step 2;
[0016] Step 3: At the same water bath temperature as step 1, continue stirring the solution of step 2 for 4-7 hours to obtain the solution of step 3;
[0017] Step 4: dilute the prepared solution of step 3 to 100 mL; and adjust the pH value to 6.4; to obtain the prepared solution of step 4;
[0018] Step 5: Filter the prepared solution in step 4 through a filter to obtain the sodium hyaluronate eye drops.
[0019] In one aspect of the present invention, in the aforementioned preparation method, the masses of the sodium chloride, potassium chloride, ε-aminocaproic acid, sodium edetate hydrate and benzalkonium chloride are 650-750 mg, 100-200 mg, 100-300 mg, 50-200 mg and 2.6-3.4 mg, respectively; the mass of the sodium hyaluronate is 250-350 mg.
[0020] In one aspect of the present invention, in the aforementioned preparation method, in step 1, the pH value is adjusted to 6.4-6.8; preferably, the pH value is adjusted to 6.4-6.6.
[0021] In one aspect of the present invention, in the aforementioned preparation method, in step 1 and step 4, dilute hydrochloric acid and / or sodium hydroxide are used to adjust the pH value.
[0022] In one aspect of the present invention, a method for preparing sodium hyaluronate eye drops is provided, the method comprising the following steps:
[0023] Step 1: Place 80 mL of water in a container, heat in a water bath at 40° C.-60° C., and sequentially add 650-750 mg of sodium chloride, 100-200 mg of potassium chloride, 100-300 mg of ε-aminocaproic acid, 50-200 mg of sodium edetate hydrate, and 2.6-3.4 mg of benzalkonium chloride; adjust the pH value to 6.4-6.8; preferably, adjust the pH value to 6.4-6.6; obtain the solution of step 1;
[0024] Step 2: Add 250-350 mg of sodium hyaluronate to the solution prepared in step 1, and stir at the same water bath temperature as step 1 until it is completely dissolved to obtain the solution prepared in step 2;
[0025] Step 3: At the same water bath temperature as step 1, continue stirring the solution of step 2 for 5.5-6.5 hours to obtain the solution of step 3;
[0026] Step 4: dilute the prepared solution of step 3 to 100 mL; and adjust the pH value to 6.4; to obtain the prepared solution of step 4;
[0027] Step 5: Filter the prepared solution in step 4 through a filter to obtain the sodium hyaluronate eye drops.
[0028] In one aspect of the present invention, the sodium hyaluronate eye drops obtained by the preparation method provided by the present invention have a weight average molecular weight (Mw) greater than 791,000.
[0029] In one aspect of the present invention, the sodium hyaluronate eye drops obtained by the preparation method provided by the present invention have a molecular weight distribution (Mw / Mn) of 2.0-2.3.
[0030] The beneficial effects of the present invention are:
[0031] The invention provides a method for preparing sodium hyaluronate eye drops, which can save the sodium hyaluronate dissolution time and the total time for producing the sodium hyaluronate eye drops, simplify the production process, improve product stability, and reduce the probability of bacterial contamination. DETAILED DESCRIPTION
[0032] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is only an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the invention of the present invention based on the disclosed content, and they should also fall within the scope of the present application.
[0033] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. Unless otherwise specified, the contents described below are all weight contents. Unless otherwise specified, it is understood that the process is carried out at room temperature.
[0034] Embodiment 1:
[0035] Embodiment 1 comprises the following steps:
[0036] Step 1: Place 80 mL of water in a container, heat in a water bath at 40° C., and sequentially add 300 mg of sodium chloride, 150 mg of potassium chloride, 200 mg of ε-aminocaproic acid, 100 mg of sodium edetate hydrate, and 3.0 mg of benzalkonium chloride; adjust the pH value to 6.4 with hydrochloric acid and / or sodium hydroxide; and obtain the solution of step 1;
[0037] Step 2: Add 300 mg of sodium hyaluronate to the solution prepared in step 1, and stir at 40° C. until completely dissolved; obtain the solution prepared in step 2; and record the dissolution time;
[0038] Step 3: Continue stirring the solution prepared in step 2 at 40° C. for 6 h to obtain the solution prepared in step 3; and take samples at 0 h, 4 h and 6 h;
[0039] Step 4: dilute the prepared solution of step 3 to 100 mL; and adjust the pH value to 6.4; to obtain the prepared solution of step 4;
[0040] Step 5: Filter the prepared solution in step 4 through a filter to obtain the sodium hyaluronate eye drops.
[0041] Embodiment 2:
[0042] The steps of Example 2 are the same as those of Example 1, except that the heating temperature of steps 1-3 is 60°C.
[0043] Comparative Example 1:
[0044] The steps of Comparative Example 1 are the same as those of Example 1, except that steps 1-3 are performed at room temperature without heating.
[0045] Comparative Example 2:
[0046] The steps of Comparative Example 2 are the same as those of Example 1, except that the heating temperature of steps 1-3 is 80°C.
[0047] Experimental Example 1: Testing product parameters obtained at different heating temperatures:
[0048] The dissolution time of sodium hyaluronate in Examples 1 and 2 and Comparative Examples 1 and 2, as well as the molecular weight and molecular weight distribution of the samples obtained at 0 h, 4 h and 6 h in step 3 were tested. The results are shown in Table 1 below:
[0049] Table 1
[0050]
[0051] It can be seen that the higher the temperature, the faster the sodium hyaluronate dissolves. The dissolution time of sodium hyaluronate at room temperature is significantly longer than that of samples at other temperatures. At 80°C, the pH value is higher than that of samples at other preparation temperatures and the variation range is large. The kinematic viscosity is lower than that of samples at other preparation temperatures. As the stirring time increases, the kinematic viscosity and molecular weight decrease significantly; therefore, the temperature range of Comparative Examples 1 and 2 is not suitable for the preparation method of sodium hyaluronate eye drops provided by the present invention.
[0052] Embodiment 3:
[0053] Embodiment 3 comprises the following steps:
[0054] Step 1: Place 80 mL of water in a container, heat in a water bath at 50° C., and sequentially add 300 mg of sodium chloride, 150 mg of potassium chloride, 200 mg of ε-aminocaproic acid, 100 mg of sodium edetate hydrate, and 3.0 mg of benzalkonium chloride; adjust the pH value to 6.0 with hydrochloric acid and / or sodium hydroxide; and obtain the solution of step 1;
[0055] Step 2: Add 300 mg of sodium hyaluronate to the solution prepared in step 1, and stir at 50° C. until completely dissolved; obtain the solution prepared in step 2; and record the dissolution time;
[0056] Step 3: Continue stirring the solution prepared in step 2 at 50° C. for 6 h to obtain the solution prepared in step 3;
[0057] Step 4: dilute the prepared solution of step 3 to 100 mL; and adjust the pH value to 6.4; to obtain the prepared solution of step 4;
[0058] Step 5: Filter the prepared solution in step 4 through a filter to obtain the sodium hyaluronate eye drops.
[0059] Embodiment 4:
[0060] The steps of Example 4 are the same as those of Example 3, except that, in step 1, the pH value is adjusted to 6.2 by hydrochloric acid and / or sodium hydroxide.
[0061] Embodiment 5:
[0062] The steps of Example 5 are the same as those of Example 3, except that, in step 1, the pH value is adjusted to 6.4 by hydrochloric acid and / or sodium hydroxide.
[0063] Embodiment 6:
[0064] The steps of Example 6 are the same as those of Example 3, except that in step 1, the pH value is adjusted to 6.6 by hydrochloric acid and / or sodium hydroxide.
[0065] Embodiment 7:
[0066] The steps of Example 7 are the same as those of Example 3, except that, in step 1, the pH value is adjusted to 6.8 by hydrochloric acid and / or sodium hydroxide.
[0067] Embodiment 8:
[0068] The steps of Example 8 are the same as those of Example 3, except that in step 1, the pH value is adjusted to 7.0 by hydrochloric acid and / or sodium hydroxide.
[0069] Experimental Example 2: Testing the stability of products with different pH values under high temperature conditions:
[0070] Examples 3-8 were left to stand at 60°C, and their pH and kinematic viscosity were tested at 0d, 10d and 30d, respectively. The results are shown in Tables 2 and 3 below:
[0071] Table 2
[0072]
[0073] Table 3
[0074]
[0075] It can be seen that after Examples 5, 6 and 7 were placed at a high temperature of 50° C. for 30 days, the pH value and kinematic viscosity of the products showed similar change trends, with no obvious changes and were relatively stable.
[0076] Embodiment 9:
[0077] The steps of Example 9 are the same as those of Example 3, except that in step 1, the pH value is adjusted to 6.5 by hydrochloric acid and / or sodium hydroxide.
[0078] Experimental Example 3: Testing the stability of products with different pH values under accelerated conditions:
[0079] Examples 4-7 and Example 9 were allowed to stand at 40°C, ≤25% RH for at least 6 months, and their respective molecular weights, molecular weight distributions and kinematic viscosities were tested at 0 day, 1 month, 3 months and 6 months. The results are shown in Tables 4 and 5 below:
[0080] Table 4
[0081]
[0082] Table 5
[0083]
[0084]
[0085] It can be seen from Table 4 and Table 5 that the overall test results of pH value and kinematic viscosity of samples with pH of 6.40-6.60 in step 1 are not much different. After 6 months, the kinematic viscosity of samples with pH of 6.20 and pH 6.80 decreased significantly. When the pH range of the production process is controlled at 6.40-6.60, the quality of the obtained product is relatively stable.
[0086] Experimental Example 4: Antibacterial ability test:
[0087] The antibacterial efficacy test method of the third part of the 2020 edition of the Chinese Pharmacopoeia was used to determine the antibacterial ability of Examples 4-7 and Example 9 after standing for 0 days and standing for 6 months, and the results are shown in Table 6 below; wherein, "reduced lg value" refers to the difference between the lg value of the number of bacteria measured at each interval and the lg value of the number of bacteria inoculated in 1mL (g) of the test sample. The antibacterial efficacy of the eye drops prepared in the above examples all reached the A standard.
[0088] Table 6
[0089]
[0090] It can be seen from Table 6 that the products of the present invention have significant antibacterial efficacy at 0 days, can significantly inhibit the growth of bacteria and fungi, and make the test bacteria unable to resume growth, and can reach the antibacterial efficacy standard of Chinese Pharmacopoeia "A"; however, the antibacterial effect of the samples of Examples 4 and 7 is significantly reduced after 6 months of acceleration, and even cannot reach the antibacterial efficacy standard of Chinese Pharmacopoeia "B". It can be seen that in the process of preparing sodium hyaluronate eye drops, pH control has a significant effect on the stability of the final product; when the pH range of the production process is controlled to be 6.40-6.60, the antibacterial ability stability of the obtained product is better.
[0091] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A sodium hyaluronate eye drop, characterized in that: The pH value of the sodium hyaluronate eye drops is 6.0-7.0; each 100 mL of the sodium hyaluronate eye drops contains the following ingredients: 250-350 mg of sodium hyaluronate, 2.6-3.4 mg of benzalkonium chloride, 650-750 mg of sodium chloride, 100-200 mg of potassium chloride, 100-300 mg of ε-aminocaproic acid and 50-200 mg of sodium edetate hydrate.
2. The sodium hyaluronate eye drops according to claim 1, characterized in that The pH value of the sodium hyaluronate eye drops is 6.4-6.
8.
3. The sodium hyaluronate eye drops according to claim 1, characterized in that The sodium hyaluronate eye drops contain the following ingredients per 100 mL: 275-325 mg of sodium hyaluronate, 2.8-3.2 mg of benzalkonium chloride, 680-720 mg of sodium chloride, 125-175 mg of potassium chloride, 175-225 mg of ε-aminocaproic acid and 75-125 mg of sodium edetate hydrate.
4. The sodium hyaluronate eye drops according to any one of claims 1 to 3, characterized in that The edetate sodium hydrate is edetate disodium.
5. A method for preparing the sodium hyaluronate eye drops according to any one of claims 1 to 4, characterized in that: The method comprises the following steps: Step 1: Place 80 mL of water in a container, heat it in a water bath at 40° C.-60° C., and sequentially add sodium chloride, potassium chloride, ε-aminocaproic acid, sodium edetate hydrate and benzalkonium chloride; adjust the pH value to 6.0-7.0; and obtain the solution of step 1; Step 2: adding sodium hyaluronate to the solution prepared in step 1, stirring at the same water bath temperature as step 1 until it is completely dissolved, to obtain the solution prepared in step 2; Step 3: At the same water bath temperature as step 1, continue stirring the solution of step 2 for 4-7 hours to obtain the solution of step 3; Step 4: dilute the prepared solution of step 3 to 100 mL; and adjust the pH value to 6.4; to obtain the prepared solution of step 4; Step 5: Filter the prepared solution in step 4 through a filter to obtain the sodium hyaluronate eye drops.
6. The method according to claim 5, characterized in that The masses of the sodium chloride, potassium chloride, ε-aminocaproic acid, sodium edetate hydrate and benzalkonium chloride are 650-750 mg, 100-200 mg, 100-300 mg, 50-200 mg and 2.6-3.4 mg respectively; the mass of the sodium hyaluronate is 250-350 mg.
7. The method according to claim 5, characterized in that In step 1, the pH was adjusted to 6.4-6.
8.
8. The method according to claim 5, characterized in that In step 1 and step 4, the pH value is adjusted using dilute hydrochloric acid and / or sodium hydroxide.
9. The method according to claim 5, characterized in that The method comprises the following steps: Step 1: Place 80 mL of water in a container, heat in a water bath at 40° C.-60° C., and sequentially add 650-750 mg of sodium chloride, 100-200 mg of potassium chloride, 100-300 mg of ε-aminocaproic acid, 50-200 mg of sodium edetate hydrate, and 2.6-3.4 mg of benzalkonium chloride; adjust the pH value to 6.4-6.8; and obtain the solution of step 1; Step 2: Add 250-350 mg of sodium hyaluronate to the solution prepared in step 1, and stir at the same water bath temperature as step 1 until it is completely dissolved to obtain the solution prepared in step 2; Step 3: At the same water bath temperature as step 1, continue stirring the solution of step 2 for 5.5-6.5 hours to obtain the solution of step 3; Step 4: dilute the prepared solution of step 3 to 100 mL; and adjust the pH value to 6.4; to obtain the prepared solution of step 4; Step 5: Filter the prepared solution in step 4 through a filter to obtain the sodium hyaluronate eye drops.
Citation Information
Cited By
Levofloxacin hydrochloride eye drop and preparation method thereof
CN122894316A
